ID

17219

Beschreibung

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00517283

Link

https://clinicaltrials.gov/show/NCT00517283

Stichworte

  1. 01.09.16 01.09.16 -
Hochgeladen am

1. September 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Type 2 Diabetes Mellitus NCT00517283

Eligibility Type 2 Diabetes Mellitus NCT00517283

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with at least 1 year history of type 2 diabetes mellitus.
Beschreibung

Type 2 diabetes mellitus

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening hba1c ≥7.0% and ≤10.0%.
Beschreibung

HbA1C

Datentyp

boolean

Alias
UMLS CUI [1]
C0202054
between the body mass index (bmi) of 19 kg/m2 and 40 kg/m2, inclusive.
Beschreibung

BMI

Datentyp

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.
Beschreibung

Investigational Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
persons who have previously completed or withdrawn from this study or any other study investigating exenatide.
Beschreibung

Study Subject Participation Status

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).
Beschreibung

drugs affecting gastrointestinal motility

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.
Beschreibung

Concomitant medication

Datentyp

boolean

Alias
UMLS CUI [1]
C2347852
subjects who have used insulin for more than 4 weeks within 3 months prior to screening.
Beschreibung

Insulin

Datentyp

boolean

Alias
UMLS CUI [1]
C0021641
blood donation of more than 500 ml in the last 3 months of screening or any blood donation within the last month.
Beschreibung

blood donation

Datentyp

boolean

Alias
UMLS CUI [1]
C0005794

Ähnliche Modelle

Eligibility Type 2 Diabetes Mellitus NCT00517283

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Type 2 diabetes mellitus
Item
subjects with at least 1 year history of type 2 diabetes mellitus.
boolean
C0011860 (UMLS CUI [1])
HbA1C
Item
subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening hba1c ≥7.0% and ≤10.0%.
boolean
C0202054 (UMLS CUI [1])
BMI
Item
between the body mass index (bmi) of 19 kg/m2 and 40 kg/m2, inclusive.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Investigational Drugs
Item
within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.
boolean
C0013230 (UMLS CUI [1])
Study Subject Participation Status
Item
persons who have previously completed or withdrawn from this study or any other study investigating exenatide.
boolean
C2348568 (UMLS CUI [1])
drugs affecting gastrointestinal motility
Item
subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
Concomitant medication
Item
subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.
boolean
C2347852 (UMLS CUI [1])
Insulin
Item
subjects who have used insulin for more than 4 weeks within 3 months prior to screening.
boolean
C0021641 (UMLS CUI [1])
blood donation
Item
blood donation of more than 500 ml in the last 3 months of screening or any blood donation within the last month.
boolean
C0005794 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video